Free Trial!
Today’s Best Stocks To Trade! Click Here
----------------------------------------------------------
To view in-depth research, click the following link: www.stockwire.com/chat
----------------------------------------------------------
L. B. Foster Company (Nasdaq:FSTR) Current Price (42.85) PITTSBURGH, Jan. 31- L.B. Foster Company (Nasdaq: FSTR - News), a leading manufacturer, fabricator, and distributor of products and services for rail, construction, energy and utility markets, today reported that its fourth quarter earnings per diluted share from continuing operations was $7.79. These results include a pre-tax gain related to the sale of the Company's investment in the DM&E Railroad of $122.9 million. Excluding this gain, earnings per diluted share from continuing operations were $0.81 compared to $0.27 in last year's fourth quarter, a 200% increase. This marks the twelfth consecutive quarter the Company has recorded an earnings increase over the prior year quarter. L. B. Foster Company engages in the manufacture, fabrication, and distribution of products for surface transportation infrastructure primarily in the United States. It operates in three segments: Rail Products, Construction Products, and Tubular Products. The Rail Products segment provides heavy and light rail, relay rail, concrete ties, insulated rail joints, rail accessories and transit products to industrial plants, contractors, railroads, mines, and mass transit systems. Its rail accessories include trackwork, ties, track spikes, bolts, angle bars, and other products to install or maintain rail lines; rail products comprise insulated rail joints and related accessories for the railroad and mass transit industries; and transit products consists of power rail, direct fixation fasteners, coverboards, and special accessories primarily for mass transit systems. This segment also offers new and relay trackwork, and engineered concrete railroad ties for the railroad and transit industries. The Construction Products segment offers sheet, pipe and bearing piling, fabricated highway products, and precast concrete buildings. The Tubular Products segment provides fusion bond and other coatings for corrosion protection on oil, gas, and other pipelines, as well as supplies special pipe products, such as water well casing, column pipe, couplings, and related products for agricultural, municipal, and industrial water wells. L. B. Foster was founded in 1902 and is headquartered in Pittsburgh, Pennsylvania.
----------------------------------------------------------
To view in-depth research, click the following link: www.stockwire.com/chat
----------------------------------------------------------
CardioVascular BioTherapeutics, Inc.
(OTC BB:CVBT) Current Price (1.41) LAS VEGAS--Jan 31--CardioVascular BioTherapeutics, Inc. (OTCBB:CVBT - News):February 1st is National Wear Red Day. The American Heart Association and CardioVascular BioTherapeutics, Inc. (OTCBB:CVBT - News) encourage women to wear red clothing to show support for the fight against women's heart disease. This support will be evident the night of January 31st as the "Welcome to Las Vegas" sign goes red in support of National Wear Red Day. CardioVascular BioTherapeutics, Inc., a development stage biopharmaceutical company, focuses on developing and marketing protein drug candidates used in the treatment of cardiovascular disease. The company uses an active pharmaceutical ingredient, the 141 amino acid form of fibroblast growth factor-1, in its drug candidates, which facilitates the growth of new blood vessels in the heart, and other tissues and organs with an impaired vascular system. Its products under development include CVBT-141A, a Phase I clinical trial completed product for use in the treatment of severe coronary heart disease; and CVBT-141B, which is in Phase I clinical trials for the treatment of diabetic, bedridden, and elderly patients suffering from wounds, open sores, and diabetic ulcers. The company also develops CVBT-141C, which has approval for Phase I clinical trials for the treatment of peripheral artery disease. In addition, CardioVascular BioTherapeutics' product portfolio includes CVBT-141D, which is under proof of concept clinical trials stage for the treatment of disc ischemia. Further, it develops CVBT-141E for the treatment of lumbar ischemia and CVBT-141H for the treatment of severe coronary heart disease'injection catheter delivery, which are under pre-clinical research and development stages. The company was founded in 1998 as CardioVascular Genetic Engineering, Inc. and changed its name to CardioVascular BioTherapeutics, Inc. in 2004. CardioVascular BioTherapeutics is headquartered in Las Vegas, Nevada.
----------------------------------------------------------
To view in-depth research, click the following link: www.stockwire.com/chat
----------------------------------------------------------
Central Gold-Trust (AMEX:GTU) Current Price (35.89) TORONTO, ONTARIO---Jan 31, 2008 -- Central Gold-Trust (Toronto:GTU-UN.TO - News)(Toronto:GTU-U.TO - News)(AMEX:GTU - News) of Ancaster, Ontario is pleased to announce that CIBC World Markets Inc. has exercised its right to increase the size of the offering of Units of Central Gold-Trust by purchasing an additional 12,000 Units of Central Gold-Trust at U.S.$36.65 per Unit, for additional gross proceeds of U.S.$439,800 to Central Gold-Trust. CIBC World Markets Inc. agreed earlier this morning to underwrite 275,000 Units for gross proceeds of U.S.$10,078,750. Central Gold-Trust, launched in April, 2003, is a passive, self governing, single purpose, closed-end trust, which holds about 98% of its net assets in unencumbered, long-term holdings of gold bullion, substantially in physical international bankers bars. Central Gold-Trust does not actively speculate with regard to short-term changes in gold prices. Central Gold-Trust's gold bullion is held unencumbered in allocated, segregated and insured safekeeping in Canada, in the treasury vaults of the Canadian Imperial Bank of Commerce. The gold bullion is physically audited by Ernst & Young in the presence of Central Gold-Trust Officers and Trustees as well as bank officials. Central Gold-Trust Units are quoted on the AMEX, symbol GTU and the TSX, symbols GTU.UN (Cdn. $) and GTU.U (U.S. $).
----------------------------------------------------------
To view in-depth research, click the following link: www.stockwire.com/chat
----------------------------------------------------------
Aethlon Medical, Inc., (OTC BB:AEMD) Current Price (0.63) SAN DIEGO-Jan 31--Aethlon Medical, Inc. (OTCBB:AEMD - News) disclosed that its Chairman and CEO, James A. Joyce, has issued the following letter to shareholders. Aethlon Medical is the developer of the Hemopurifier , a first-in-class medical device to treat infectious disease. The Hemopurifier addresses the largest opportunity in infectious disease, the treatment of drug and vaccine resistant viruses. Regulatory and commercialization initiatives in the United States are focused on bioterror threats, while international initiatives are directed towards naturally evolving pandemic threats, and chronic infectious disease conditions including Hepatitis-C (HCV) and the Human Immunodeficiency Virus (HIV). Collaborative studies to demonstrate utility of the Hemopurifier are being conducted with researchers at the Government of India's National Institute of Virology (NIV), The Centers for Disease Control and Prevention (CDC), The United States Army Medical Research Institute of Infectious Diseases (USAMRIID), and The Southwest Foundation for Biomedical Research (SFBR). Aethlon recently demonstrated safety of the Hemopurifier in a 24-treatment human study and has received approval to continue further humans studies at The Fortis Hospital in India. The Company has also submitted an Investigational Device Exemption (IDE) to the U.S. Food and Drug Administration (FDA) related to advancing the Hemopurifier as a broad-spectrum treatment countermeasure against category "A" bioterror threats. Additional information on Aethlon Medical and its Hemopurifier technology can be accessed at www.aethlonmedical.com.
----------------------------------------------------------
About Stockwire: Stockwire is one of the largest communities for Micro Cap Investors. We are the only place on the internet to provide LIVE CHAT ROOMS for dedicated stocks.
We have also pioneering a new way to research companies before you invest them. It's called a Stockumentary. A Stockumentary is a documentary on a publicly traded company. Imagine a Dateline NBC segment, but on a publicly traded company. We are the first company to ever bring this type of quality research to investors in this format.
The Stockumentary has video interviews with management, product demos, video tours of office or factory, research reports, sec filings and much more. All of this is delivered to investors in high quality video, either by mail or email.
Stockwire.com is owned by Stockwire Research Group Inc. (SRGI) and is an independent electronic publication committed to providing our readers with factual information on selected publicly traded companies.
As detailed below, this publication accepts compensation from some of the companies from which it features. To the degrees listed herein, this Newsletter should not be regarded as an independent publication. All statements and expressions are the sole opinions of the editors and are subject to change without notice. A profile, description, or other mention of a company in the Newsletter is neither an offer nor solicitation to buy or sell any securities mentioned.
While we believe all sources of information to be factual and reliable, in no way do we represent or guarantee the accuracy thereof, nor the statements made herein.
We encourage our readers to invest carefully and read the investor information available at the web sites of the Securities and Exchange Commission ("SEC") at www.sec.gov and/or the National Association of Securities Dealers ("NASD") at www.nasd.com. The NASD has published information on how to invest carefully at its web site.
Readers can review all public filings by companies at the SEC's EDGAR page. www.sec.gov/edgar.shtml
Stockwire.com is an independent electronic publication committed to providing our readers with factual information on selected publicly traded companies. Stockwire.com is not a registered investment advisor or broker-dealer. All companies are chosen on the basis of certain financial analysis and other pertinent criteria with a view toward maximizing the upside potential for investors while minimizing the downside risk, whenever possible.
From time to time SRGI sells shares in the open market it receives as compensation for coverage of client companies. Since the shares are received as compensation for services as previously disclosed, and not for investment purposes, the editors do not view the sale of the shares as contradictory to any advice delivered in the content. This should be viewed as a conflict of interest by shareholders or prospective shareholders of the client companies.
Moreover, as detailed below, this publication accepts compensation from third party consultants and/or companies which it features on Stockwire.com. To the degrees enumerated herein, this newsletter and website should not be regarded as an independent publication.
The editor, members of the editor's family, and/or entities with which the editor is affiliated aside from Stockwire Research Group Inc. (SRGI) itself, are forbidden by company policy to own, buy, sell or otherwise trade stock for their own benefit in the companies who appear in the publication unless specifically disclosed in the newsletter.
THE READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK. THE INFORMATION FOUND IN THIS PROFILE IS PROTECTED BY THE COPYRIGHT LAWS OF THE UNITED STATES AND MAY NOT BE COPIED, OR REPRODUCED IN ANY WAY WITHOUT THE EXPRESSED, WRITTEN CONSENT OF THE EDITORS OF STOCKWIRE.COM.
We often accept restricted shares of company stock; by SEC regulations, restricted shares cannot be sold into the market for a period of at least one year from the time that the shares are issued. In such cases, we detail in the Disclaimer the specific term of any restrictions. We also receive compensation in the form of stock options, in which case we receive the right to buy shares of the stock of the company at issue, at a specified time and a specified price. In such circumstances, we specify on our Disclaimer the terms of the options received. On occasion, we also accept free-trading shares in a company that we cover. However, by policy we generally do not buy or sell any shares of a company's stock within three trading days after any such company's profile, commentary, or other company-specific information is disseminated on Stockwire.com Web site. In cases where we do trade within the three day window, our volume will never represent more than 5% of the daily volume, thereby minimizing any effect we could have on the potential price movement.
While our policies as detailed above are designed to minimize any impact upon our members of a conflict of interest between our company and our members, each member should be fully aware that such potential and actual conflicts of interest may well exist due to the compensation structure detailed herein. For this reason, and because the information contained on Stockwire.com is updated on a regular basis as circumstances change, each member is strongly encouraged to periodically review the Profile Compensation section at http://www.stockwire.com/disclaimer_profiles.htm
CONTACT: The Stockwire Group Tel: +1 512 358 8440 e-mail: info@stockwire.com
M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
